University of Nottingham and Lipoxen plc join forces to fight liver disease

   
   
04 Nov 2008 14:04:00.000

PA 272/08

The University of Nottingham has joined forces with bio-pharmaceutical company Lipoxen plc to develop improved drug delivery methods for the treatment for viral hepatitis.

Researchers aim to deliver antiviral drugs direct to the liver, by means of nanoparticles and liposomes that will target the affected organ more specifically, to suppress or eliminate the virus, as well as reducing the harmful side effects of untargeted treatment.

Lipoxen plc, a bio-pharmaceutical company specialising in the development of high-value biological therapies including vaccines and oncology drugs, has entered into a research agreement with The University of Nottingham to develop new enhanced formulations of antiviral drugs for the treatment of liver diseases such as viral hepatitis caused by hepatitis C (HCV).

Click here for full story

The two parties will test novel proprietary formulations based on liposome and nanoparticle delivery in order to achieve enhanced therapeutic effects, by delivering the drugs directly to the liver. This approach is also expected to reduce the toxicity of antiviral drugs used to treat liver disease, by limiting their uptake by surrounding tissues and by red blood cells. The project is receiving funding from the East Midlands’ bioKneX Industrial Partnership Scheme.

Hepatitis due to hepatitis C virus infection is a growing problem already affecting 150-200 million people worldwide. In recent years the pharmaceutical industry has invested considerable sums in attempts to develop new drugs for hepatitis C, but unfortunately nearly all of these drugs have failed in clinical development, or have met with only limited commercial success — mainly due to systemic toxicity that has harmful side-effects on other parts of the body besides the liver.

Lipoxen and The University of Nottingham’s project is designed to address this systemic toxicity of anti-hepatitis C drugs, which limits the dose at which they can be administered and thereby compromises their efficacy, by engineering their selective delivery to the liver using nanoparticles and liposomes. By improving delivery of the drug specifically to the affected organ, the project seeks to greatly improve the efficacy of anti-hepatitis C drugs by allowing them to be given at higher — ie. more effective — doses.

The two parties will initially work on developing a new proprietary “super generic” formulation of ribavirin, the most commonly used antiviral drug to treat viral hepatitis. This commercially attractive product, which will be based on liposome or nanoparticle delivery, will be used in combination with pegylated–interferon. This combination is the currently accepted optimal regimen for treatment of chronic hepatitis C.

Once this has been achieved the two parties intend to look at improving the delivery of other antiviral drugs for the treatment of hepatitis C that have failed to reach the market due to problems which could potentially be resolved by these novel formulation technologies. Failed anti-hepatitis C drugs include development candidates from, amongst others, GlaxoSmithKline, Boehringer Ingelheim and Wyeth.

Will Irving, Professor of Virology at The University of Nottingham, said: “We are delighted to be involved in this exciting project. If we can succeed in delivering increased doses of ribavirin to the infected liver through our novel delivery systems, it is highly likely we will improve treatment response rates, which are currently limited mostly by the amount of ribavirin an individual patient can tolerate. In addition, such a ‘proof of principle’ would open up other opportunities for the use of powerful antiviral drugs that are also limited by their systemic toxicities.

“We have a long-term research programme into many aspects of hepatitis C virus infection in The University of Nottingham, and have developed systems in the laboratory for testing drug activity which will underpin our experiments in this project. Lipoxen have an established track record of production of liposomal formulations, so this is an ideal partnership. In addition, we are planning to test and compare polymer nanoparticle delivery vehicles with liposomes, taking advantage of the considerable expertise in nanoparticle technology that exists within The University of Nottingham.”

M. Scott Maguire, Chief Executive Officer of Lipoxen, said: “We are very excited to be working with The University of Nottingham on this project as we believe that by combining our expertise in liposomal and nanoparticle drug formulation with their tissue engineering and molecular virology expertise, we can develop a new “direct to liver” delivery solution to improve the effectiveness of hepatitis C drugs.

“Our initial target will be to demonstrate the value of this new delivery approach using ribavirin, the most widely-used drug globally to treat viral hepatitis.

“Once we have developed this new formulation we believe we can significantly extend its commercial potential in the field of drug delivery to the liver by taking advantage of the opportunity to resurrect several ‘near-miss’ new drug candidates from major pharma companies that were being developed for the treatment of HCV infection.”

— Ends —

The IMAGE above is a 3D artists' impression of the HCV virus.

Notes to editors:

Hepatitis-C is particularly serious in HIV-infected patients who are now surviving longer due to the effectiveness of combination drug therapies against HIV. Existing treatments for hepatitis C virus are only partially effective. Even patients who do not have a HIV co-infection and who receive “best standard of care” generally have only a 50-80 per cent chance of being cured by drug treatments.  Patients who do not achieve cure are liable to develop fibrosis, cirrhosis, cancer and failure of the liver, and may require liver transplantation.

Lipoxen plc is a biopharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs. Products currently under development include improved formulations of important biologicals such as erythropoietin (EPO), G-CSF, insulin and Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a long acting insulin and long-acting EPO. These novel products, which are based on Lipoxen’s proprietary PolyXen® technology, each address markets in excess of US$1 billion.
Lipoxen’s technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins naturally. Lipoxen has two further naturally-derived proprietary delivery technologies, ImuXen® and a related liposomal technology for the formulation of cytotoxic oncology drugs, which are being developed to enhance the efficacy and safety of various vaccines such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company’s proprietary delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited (one of the world’s leading vaccine companies, India’s largest biotech company and a major shareholder in Lipoxen) and has license agreements in place with Baxter International and InterVet, a leading animal health company.

The University of Nottingham is ranked in the UK's Top 10 and the World's Top 100 universities by the Shanghai Jiao Tong (SJTU) and Times Higher (THE) World University Rankings.

It provides innovative and top quality teaching, undertakes world-changing research, and attracts talented staff and students from 150 nations. Described by The Times as Britain's "only truly global university", it has invested continuously in award-winning campuses in the United Kingdom, China and Malaysia. Twice since 2003 its research and teaching academics have won Nobel Prizes. The University has won the Queen's Award for Enterprise in both 2006 (International Trade) and 2007 (Innovation — School of Pharmacy), and was named ‘Entrepreneurial University of the Year’ at the 2008 Times Higher Education Awards.
 
Its students are much in demand from 'blue-chip' employers. Winners of Students in Free Enterprise for four years in succession, and current holder of UK Graduate of the Year, they are accomplished artists, scientists, engineers, entrepreneurs, innovators and fundraisers. Nottingham graduates consistently excel in business, the media, the arts and sport. Undergraduate and postgraduate degree completion rates are amongst the highest in the United Kingdom.

Story credits

More information is available from Professor Will Irving , School of Molecular Medical Sciences, University of Nottingham, on +44 (0)115 823 0752, will.irving@nottingham.ac.uk; M. Scott Maguire, Chief Executive Officer, Lipoxen, +44 (0)20 7691 3583; Heather Keohane/David Dible at Citigate Dewe Rogerson on +44 (0)20 7638 9571, heather.keohane@citigatedr.co.uk

Tim Utton

Tim Utton - Deputy Director of Communications

Email: tim.utton@nottingham.ac.uk Phone: +44 (0)115 846 8092 Location: University Park

Additional resources

No additional resources for this article

Related articles

Award recognises initiative with potential to transform liver care

Published Date
Wednesday 27th November 2013

Media Relations - External Relations

The University of Nottingham
C Floor, Pope Building (Room C4)
University Park
Nottingham, NG7 2RD

telephone: +44 (0) 115 951 5798
email: communications@nottingham.ac.uk